Purpose or Objective: Monte Carlo (MC) recalculation of spot-scanning proton therapy treatment plans can provide an independent verification of monitor units required for delivery, and reduce the time treatment rooms need to be reserved for patient specific QA. We describe the development of such a MC verification system for a clinical facility.
Purpose or Objective: Monte Carlo (MC) recalculation of spot-scanning proton therapy treatment plans can provide an independent verification of monitor units required for delivery, and reduce the time treatment rooms need to be reserved for patient specific QA. We describe the development of such a MC verification system for a clinical facility.
Material and Methods:
Realistic clinical beam models were developed by matching simulations (using GATE/GEANT4) to measurements made in a clinical beamline. They consist of a tuned physics list, a lookup table relating each of the 115 nominal beam energies to a tuned spot energy (mean and standard deviation) and phase space parameters which allow spot sizes to be properly modeled for any combination of energy and nozzle extension. For all beam energies simulations accurately reproduce both integral depth dose profiles (>97% of data-points pass a local gamma analysis at 2%/2mm) and lateral profiles measured in air and in solid water (with a 0.2 mm maximum difference). The model was further validated against a series of simple test plans which were optimized in the clinical Treatment Planning System (TPS) to produce uniform dose volumes at various depths in water.The automated MC system can process, simulate and analyse treatment plans without user input once it receives the TPS files.
Results:
The system was tested for a three field (11k spot) base of skull treatment plan computed in a patient CT dataset. Simulations were split into 40 calculations over a 10 quadcore CPU cluster, requiring <30 minutes to achieve dosimetric uncertainties (within the 90% isodose volume) of <1%. The figure demonstrates the broad agreement between the TPS (left) and the MC simulation (right). The local gamma pass rate between the two (bottom) is 97% at 4%/4mm (green voxels pass, red / blue voxels fail). This should be interpreted in the context of this being a highly inhomogeneous target site: Differences occurred only in heterogeneous regions where the TPS's analytical dose calculation would be expected to model dose deposition less accurately than MC systems. For example, the MC simulations predict a lower dose around the sinus air cavities than the TPS.
Conclusion:
We have demonstrated that the MC verification system can accurately reproduce the dose distribution predicted by a clinical TPS. Further validation work is ongoing using a variety of plans and phantom measurements. Once clinically commissioned, the system can be used as an independent dose checker, reducing on-set verification time. Purpose or Objective: To establish the workflow & methodology and to perform an experimental validation of treatment plan conversion from Tomotherapy HD machine (Accuray) using dynamic jaws to a True Beam (Varian) Linac. For this purpose, the RayStation (RS) TPS using fallback planning (RFP) is currently tested. An end-to-end set of phantom configurations of increasing complexity are presented. The ultimate goal is to validate this process in order to minimize the impact of machine downtime on patient treatments.
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Material and Methods:
Four phantom based treatment plans were generated in the Tomotherapy Planning Station. These plans were mimicked with RFP for the TrueBeam using X6-FFF dual-arc VMAT. The first three cases planned on the Cheese Phantom (Std. Imaging) consisted of 1 to 4 target dose levels and 3 OARs, using heterogeneous inserts for the last one. The 4th case was an integrated boost H&N treatment with 3 target dose levels planned on an anthropomorphic phantom (H&N, IBA). Original Helical Tomotherapy (HT) and RS fallback plans were delivered respectively on each machine. Ion chamber (A1SL, Std. Imaging) and Gafchromic EBT3 (ISP) films were used to measure absolute and planar doses. First, for both machines beam delivery vs. treatment plan was evaluated as a baseline for absolute dose, gamma (γ) passing rate (criteria 3%/3mm) and overall uncertainties. Secondly, in order to ensure that the difference between the two calculated dose distributions (TPS_TOMO / TPS_RAYSTATION) matched the differences between the two measured film dose distributions (Film_TOMO / Film_RAYSTATION), a γ difference (5%/5mm) was performed.
Results: First, gamma evaluation was (99.1±0.6)% for HT and (99.5±0.4)% for RS fallback plans while absolute dose differences between calculations and ion chamber measurements were respectively 0.9% for HT and -0.7% for RS on average for all end-to-end tests. Secondly, average γ difference between calculated doses TPS_TOMO /
